タンパク質治療薬市場：現状分析・予測 (2022年～2028年)

世界のタンパク質治療薬の市場規模は2022年から2028年にかけて約6.3%のCAGRで成長すると予測されています。

自己免疫疾患、外来物質、癌に対する防御を提供するワクチン製造に向けた治療用タンパク質の使用が同市場の成長を促進する見通しです。また、プロテオミクス研究の成長により、人間の健康を大幅に改善する可能性を秘めた新しいタンパク質薬の出現が増加し、市場を牽引すると期待されています。

当レポートでは、世界のタンパク質治療薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、法規制環境、需給動向、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法・前提因子

第3章 市場概要

第4章 エグゼクティブサマリー

第5章 COVID-19：タンパク質治療薬市場への影響

第6章 タンパク質治療薬市場：収益の推移・予測

第7章 市場洞察：タイプ別

• モノクローナル抗体
• インスリン
• 融合タンパク質
• エリスロポエチン
• インターフェロン
• その他

第8章 市場洞察：用途別

• 癌
• 代謝障害
• 免疫疾患
• 血液疾患
• その他

第9章 市場洞察：タンパク質機能別

• 酵素・調節アクティビティ
• 特殊ターゲティングアクティビティ
• ワクチン
• その他

第10章 市場洞察：エンドユーザー別

• 病院・診療所
• 専門センター
• その他

第11章 市場洞察：地域別

• 北米
• 欧州
• アジア太平洋
• その他の地域

第12章 タンパク質治療薬市場：市場力学

• 市場促進要因
• 市場課題
• 影響分析

第13章 タンパク質治療薬市場：市場機会

第14章 タンパク質治療薬市場：：市場動向

第15章 政策と規制の枠組み

第16章 需要サイド・供給サイドの分析

• 需要サイド分析
• 供給サイド分析

第17章 バリューチェーン分析

第18章 競合シナリオ

第19章 企業プロファイル

• Abbott Laboratories
• Amgen Inc.
• Baxter International Inc.
• Eli Lilly And Company
• F. Hoffmann La Roche Ltd
• Johnson and Johnson
• Merck and Co., Inc.
• Novo Nordisk AS
• Pfizer Inc.
• Sanofi

第20章 免責事項

Global protein therapeutics market is expected to register a CAGR of around ~6.3% over the period of 2022-2028. This is mainly due to the use of therapeutic proteins for manufacturing vaccines as they provide defense against autoimmune diseases, foreign agents, and cancer is likely to promote the market. Also, Protein therapeutics have stringent government regulations coupled with the growing focus of major stakeholders in the healthcare industry to adopt to make protein therapeutics products more sustainable with fewer side effects and cost-effective. Major pharmaceutical companies are investing heavily in their products due to the rising prevalence of chronic diseases, and the growing geriatric population. According to Union for International Cancer Control (UICC), the world's population is aging rapidly, with 703 million people worldwide above the age of 65 years, representing 9.1% of the global population. Furthermore, Population aging will have consequences for cancer control globally as cancer is more prevalent in older adults. In addition, protein therapy is similar to gene therapy, which involves protein delivery in specific amounts to the body to facilitate the precise functioning of different glands and other organs in the body. Moreover, growth in proteomic research is expected to lead to an increase in the emergence of new protein drugs and drugs that have the potential to significantly improve human health which drives the market. Therefore, the market for protein therapeutics is expected to witness significant growth during the forecast period.

Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann La Roche Ltd, Johnson and Johnson, Merck and Co., Inc., Novo Nordisk AS, Pfizer Inc., Sanofi are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst application, metabolic disorders are expected to witness significant CAGR during the forecast period"

Based on application, the market is categorized into cancer, metabolic disorders, immunologic disorders, hematological disorders, and others. Among these, metabolic disorders are expected to witness a significant CAGR during the forecast period. This is mainly due to the requirement for quality drugs and versatile therapies for disease treatment, especially coronary heart disease, diabetes, and stroke which is expected to boost the growth of this segment. According to the American Heart Association, 47 million Americans have it. That's almost a staggering 1 out of every 6 people in 2021. Therefore, this segment rising due to the use of protein therapeutics in the global market is likely to boost the demand for protein therapeutics.

"Amongst protein function, enzymatic and regulatory activity category accounted for the significant share in the market in 2020"

Based on protein function, the market is classified into enzymatic and regulatory activity, special targeting activity, vaccines, and others. Amongst protein functions, the enzymatic and regulatory activity category accounted for a significant share of the market. Based on their pharmacological activity, they can be divided into five groups: (a) replacing a protein that is deficient or abnormal; (b) augmenting an existing pathway; (c) providing a novel function or activity; (d) interfering with a molecule or organism; and (e) delivering other compounds or proteins, such as a radionuclide, cytotoxic drug, or effector protein.

"Amongst end-user, hospitals and clinics category accounted for the significant share in the market in 2020"

Based on end-user, the market is categorized into hospitals and clinics, specialty centers, and others. Among these, hospitals and clinics are expected to witness the highest CAGR during the forecast period. The hospitals and clinics are estimated to add to the growing need for protein therapeutics products which is expected to drive the growth of this segment. Also, the use of therapeutic proteins for manufacturing vaccines as they provide defense against autoimmune diseases, foreign agents, and cancer is likely to promote the market. For instance, In June 2022, Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

"North America to witness significant growth during the forecast period"

North America is expected to show the highest CAGR growth in the protein therapeutics market. The major contributors to the growth of this market are US and Canada. This is mainly due to the growing various protein therapeutics and highly developed economy, high product adoption rates, awareness about protein-based therapeutics, and surge in strategic developments among key players of the market in the U.S. economy. For instance, In July 2020, Kymera Therapeutics Inc. announced the company has entered into a multi-program strategic collaboration with Sanofi (NASDAQ: SNY) to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. Moreover, the development of advanced protein therapeutics by major companies and the diagnostics industry owing to the presence of well-established market players and frequent product launches in the region.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

Global protein therapeutics market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Protein Therapeutics Market
• 2.2. Research Methodology of the Protein Therapeutics Market
• 2.4. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL PROTEIN THERAPEUTICS MARKET COVID-19 IMPACT

6 GLOBAL PROTEIN THERAPEUTICS MARKET REVENUE (USD BN), 2019-2027F

7 MARKET INSIGHTS BY TYPE

• 7.1. Monoclonal Antibodies
• 7.2. Insulin
• 7.3. Fusion Protein
• 7.4. Erythropoietin
• 7.5. Interferon
• 7.6. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Cancer
• 8.2. Metabolic Disorders
• 8.3. Immunologic Disorders
• 8.4. Hematological Disorders
• 8.5. Others

9 MARKET INSIGHTS BY PROTEIN FUNCTION

• 9.1. Enzymatic and Regulatory Activity
• 9.2. Special Targeting Activity
• 9.3. Vaccines
• 9.4. Others

10 MARKET INSIGHTS BY END-USER

• 10.1. Hospitals and Clinics
• 10.2. Specialty Centers
• 10.3. Others

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. UK
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Australia
  • 11.3.5. Rest of Asia-Pacific
• 11.4. Rest of World

12 PROTEIN THERAPEUTICS MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 PROTEIN THERAPEUTICS MARKET OPPORTUNITIES

14 PROTEIN THERAPEUTICS MARKET TRENDS

15 POLICY & REGULATORY FRAMEWORK

16 DEMAND AND SUPPLY-SIDE ANALYSIS

• 16.1. Demand Side Analysis
• 16.2. Supply Side Analysis

17 VALUE CHAIN ANALYSIS

18 COMPETITIVE SCENARIO

• 18.1. Competitive Landscape
  • 18.1.1. Porter's Five Forces Analysis

19 COMPANY PROFILED

• 19.1. Abbott Laboratories
• 19.2. Amgen Inc.
• 19.3. Baxter International Inc.
• 19.4. Eli Lilly And Company
• 19.5. F. Hoffmann La Roche Ltd
• 19.6. Johnson and Johnson
• 19.7. Merck and Co., Inc.
• 19.8. Novo Nordisk AS
• 19.9. Pfizer Inc.
• 19.10. Sanofi

20 DISCLAIMER